We are live on ! Find out more
IRON icon

Disc Medicine

215 hedge funds and large institutions have $3.13B invested in Disc Medicine in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 75 increasing their positions, 63 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

461% more call options, than puts

Call options by funds: $26.6M | Put options by funds: $4.75M

77% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 22

19% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 63

17% more capital invested

Capital invested by funds: $2.67B → $3.13B (+$457M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

6% more funds holding

Funds holding: 203215 (+12)

2.06% more ownership

Funds ownership: 109.8%111.86% (+2.1%)

Holders
215
Holders Change
+12
Holders Change %
+5.91%
% of All Funds
2.6%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.08%
New
39
Increased
75
Reduced
63
Closed
22
Calls
$26.6M
Puts
$4.75M
Net Calls
+$21.9M
Net Calls Change
+$3.6M

IRON Hedge Fund Activity: Q2 2026 in Review

215 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q2 2026, worth a combined $3.13B — up 17% from $2.67B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new IRON positions and 22 closed out — a net gain of 17 holders — while 75 added to existing stakes and 63 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $58.4M. The largest seller was OrbiMed, cutting an estimated $48.8M.

  • 215 institutional investors held Disc Medicine (IRON) as of Q2 2026, up from 203 in Q1 2026.
  • Funds reported $3.13B of Disc Medicine stock for Q2 2026, up 17% quarter-over-quarter.
  • 39 funds opened new Disc Medicine positions in Q2 2026 and 22 closed out, a net change of +17 holders.
  • The largest Disc Medicine buyer in Q2 2026 was Vestal Point Capital, an estimated $58.4M added.
  • The largest Disc Medicine seller in Q2 2026 was OrbiMed, an estimated $48.8M sold.

Based on aggregated 13F filings for Q2 2026.